文献速递心力衰竭与心肌病

口服酮酯治疗射血分数降低心力衰竭患者的心血管效应:随机对照双盲试验

Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial.
PubMed 文献 · Circulation · 2024-03-27

该随机双盲交叉研究纳入24例非糖尿病射血分数降低心力衰竭患者,比较14天酮酯与等热量对照方案。结果显示酮酯治疗与静息心输出量升高、肺毛细血管楔压降低相关,运动时楔压更低、心输出量更高,NT-proBNP降低18%,左室射血分数提高。

要点

  • 酮酯14天治疗可提高静息心输出量并降低肺毛细血管楔压。
  • 运动负荷下酮酯治疗与更低肺毛细血管楔压和更高心输出量相关。
  • 探索性分析显示酮酯治疗与NT-proBNP降低18%及左室射血分数提高相关。

核心结论

  • 14天酮酯治疗与静息心输出量升高、充盈压降低、心脏容积减小及NT-proBNP降低相关,且在最佳药物治疗基础上实现。

研究设计与样本

  • 随机、双盲、交叉研究,纳入24例非糖尿病射血分数降低心力衰竭患者(17例男性;65±9岁;均为白人)。
  • 患者接受14天酮酯和14天等热量非酮酯对照方案,每日4次给药,洗脱期14天,每个治疗期后行右心导管、超声心动图和采血。

主要发现

  • 谷浓度时静息心输出量酮酯组高于等热量对照组(5.2±1.1 L/min 对 5.0±1.1 L/min;差值0.3 L/min [95%CI 0.1-0.5])。
  • 谷浓度时肺毛细血管楔压酮酯组低于对照组(8±3 mm Hg 对 11±3 mm Hg;差值-2 mm Hg [95%CI -4至-1])。
  • 给药后上述变化放大;运动各强度下酮酯治疗与平均运动肺毛细血管楔压降低(-3 mm Hg [95%CI -5至-1])和平均心输出量升高(0.5 L/min [95%CI 0.1-0.8])相关,低至中等稳态运动时差异显著,峰值运动时无显著差异。
  • 代谢当量在两种治疗间保持相似。
  • 探索性分析中,酮酯治疗与NT-proBNP降低18%(差值-98 ng/L [95%CI -185至-23])、左室射血分数升高(37±5% 对 34±5%;P=0.01)及左房和左室容积降低相关。

临床怎么用

  • 对于射血分数降低心力衰竭患者,在最佳药物治疗基础上,酮酯治疗可能通过改善静息和运动血流动力学及降低NT-proBNP带来获益。
  • 需注意本研究为小样本探索性研究,酮酯的临床常规应用尚需进一步验证。

局限性

  • 样本量较小(24例),且均为白人非糖尿病患者,结果外推受限。
  • 代谢当量无显著改善,峰值运动血流动力学差异不显著。
  • 探索性分析结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heart failure triggers a shift in myocardial metabolic substrate utilization, favoring the ketone body 3-hydroxybutyrate as energy source. We hypothesized that 14-day treatment with ketone ester (KE) would improve resting and exercise hemodynamics and exercise capacity in patients with heart failure with reduced ejection fraction. METHODS: In a randomized, double-blind cross-over study, nondiabetic patients with heart failure with reduced ejection fraction received 14-day KE and 14-day isocaloric non-KE comparator regimens of 4 daily doses separated by a 14-day washout period. After each treatment period, participants underwent right heart catheterization, echocardiography, and blood sampling at plasma trough levels and after dosing. Participants underwent an exercise hemodynamic assessment after a second dosing. The primary end point was resting cardiac output (CO). Secondary end points included resting and exercise pulmonary capillary wedge pressure and peak exercise CO and metabolic equivalents. RESULTS: We included 24 patients with heart failure with reduced ejection fraction (17 men; 65±9 years of age; all White). Resting CO at trough levels was higher after KE compared with isocaloric comparator (5.2±1.1 L/min versus 5.0±1.1 L/min; difference, 0.3 L/min [95% CI, 0.1-0.5), and pulmonary capillary wedge pressure was lower (8±3 mm Hg versus 11±3 mm Hg; difference, -2 mm Hg [95% CI, -4 to -1]). These changes were amplified after KE dosing. Across all exercise intensities, KE treatment was associated with lower mean exercise pulmonary capillary wedge pressure (-3 mm Hg [95% CI, -5 to -1] ) and higher mean CO (0.5 L/min [95% CI, 0.1-0.8]), significantly different at low to moderate steady-state exercise but not at peak. Metabolic equivalents remained similar between treatments. In exploratory analyses, KE treatment was associated with 18% lower NT-proBNP (N-terminal pro-B-type natriuretic peptide; difference, -98 ng/L [95% CI, -185 to -23]), higher left ventricular ejection fraction (37±5 versus 34±5%; P=0.01), and lower left atrial and ventricular volumes. CONCLUSIONS: KE treatment for 14 days was associated with higher CO at rest and lower filling pressures, cardiac volumes, and NT-proBNP levels compared with isocaloric comparator. These changes persisted during exercise and were achieved on top of optimal medical therapy. Sustained modulation of circulating ketone bodies is a potential treatment principle in patients with heart failure with reduced ejection fraction. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05161650.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Berg-Hansen, Gopalasingam, Christensen, et al. Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial. Circulation. 2024. PMID: 38533643. doi:10.1161/CIRCULATIONAHA.123.067971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。